Overview

Naltrexone for Impulse Control Disorders in Parkinson's Disease

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effectiveness of naltrexone in reducing ICD symptoms in Parkinson's disease patients taking a dopamine agonist.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
Michael J. Fox Foundation for Parkinson's Research
Treatments:
Naltrexone